Cost-Effectiveness Analysis of Adjuvant Hormonal Treatments for Women with Postmenopausal Hormone-Receptor Positive Early Breast Cancer in the Korean Context | Zendy

Hye-Jae Lee | Zendy; TaeJin Lee | Zendy; Bong-Min Yang | Zendy; Jun Won Min | Zendy

Open Access

Cost-Effectiveness Analysis of Adjuvant Hormonal Treatments for Women with Postmenopausal Hormone-Receptor Positive Early Breast Cancer in the Korean Context

Author(s) -

Hye-Jae Lee,

TaeJin Lee,

Bong-Min Yang,

Jun Won Min

Publication year - 2010

Publication title -

journal of breast cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1

H-Index - 36

eISSN - 2092-9900

pISSN - 1738-6756

DOI - 10.4048/jbc.2010.13.3.286

Subject(s) - anastrozole , medicine , letrozole , tamoxifen , breast cancer , hazard ratio , oncology , gynecology , context (archaeology) , aromatase inhibitor , exemestane , cancer , aromatase , confidence interval , paleontology , biology

• Breast cancer is the most common cancer among women in South Korea. A total of 11,275 women were newly diagnosed as having breast cancer in 2006 and the agestandardized incidence rate per 100,000 was 35.5. (1) • Anastrozole and Letrozole are the third generation aromatase inhibitors, and they have been demonstrated to be more effective than tamoxifen as the first-line treatment for early breast cancer. • Anastrozole has shown more favorable disease-free survival (hazard ratio [HR], 0.83; 95% confidence interval [CI], 0.73-0.94; p=0.005) and a longer time to recurrence (HR, 0.74; 95% CI, 0.64-0.87; p=0.0002) versus tamoxifen on the completed treatment analysis of the ATAC trial, which was performed in postmenopausal women with early breast cancer. (3) Background

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research